The FDA on Monday approved a pill from Allergan to treat migraine in adults. The treatment, ubrogepant (Ubrelvy), is part of a new class of migraine medicines designed to block calcitonin gene-related peptide (CGRP), a protein thought to play a role in pain transmission.
Ubrogepant is the first CGRP drug in tablet form to get the FDA’s nod. The Allergan (NYSE: AGN) pill is meant to be taken immediately after the onset of migraine by adults. Ubrogepant is indicated regardless of whether migraine is accompanied by aura, strange sensory disturbances that can accompany the condition.
Allergan licensed ubrogepant from Merck (NYSE:… Read more »
UNDERWRITERS AND PARTNERS